| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Cytokine Biology, Center for Biologics Evaluation and Research, FDA [R. W. K.], Radiation Oncology Branch [A. R., S. M., M. W. B., O. A. G.], and Metabolism Branch [R. J., T. A. W.], National Cancer Institute, NIH, Bethesda, Maryland 20892
One factor that is critical to the potential effectiveness of radioimmunotherapy is the design of radiometal-chelated antibodies that will be stable in vivo. Stability in vivo depends on the condition that both the chelate linkage and radiolabeling procedures not alter antibody specificity and biodistribution. In addition, synthesis and selection of the chelating agent is critical for each radiometal in order to prevent inappropriate release of the radiometal in vivo. In the present study, we compare the in vivo stability of seven radioimmunoconjugates that use different polyaminocarboxylate chelating agents to complex yttrium-88 to the mouse anti-human interleukin-2 receptor monoclonal antibody, anti-Tac. Chelate linkage and radiolabeling procedures did not alter the immunospecificity of anti-Tac. In order to assess whether yttrium was inappropriately released from the chelate-coupled antibody in vivo, iodine-131-labeled and yttrium-88 chelate-coupled antibodies were simultaneously administered to the same animals to correlate the decline in yttrium and radioiodinated antibody activity. The four stable yttrium-88 chelate-coupled antibodies studied displayed similar iodine-131 and yttrium-88 activity, indicating minimal elution of yttrium-88 from the complex. In contrast, the unstable yttrium-88 chelate-coupled antibodies had serum yttrium-88 activities that declined much more rapidly than their iodine-131 activities, suggesting loss of the radiolabel yttrium-88 from the chelate. Furthermore, high rates of yttrium-88 elution correlated with deposition in bone. Four chelating agents emerged as promising immunotherapeutic reagents: isothiocyanate benzyl DTPA and its derivatives 1B3M, MX, and 1M3B. All four isothiocyanate agents showed prolonged yttrium-88 vascular survival which was essentially identical to that of their iodine-131 activity with only minimum accumulation (1.4–1.8%/g) of the yttrium-88 injected dose into bone. Thus, these four chelating agents were very stable in vivo and suitable for yttrium-monoclonal antibody radioimmunotherapy.
1 To whom requests for reprints should be addressed at Building 29A, Room 2A11, HFB-500, 8800 Rockville Pike, Bethesda, MD 20892.
Received 10/ 4/88. Revised 2/15/89. Accepted 2/16/89.
This article has been cited by other articles:
|
|
 |
|
  D. A. Vallera, M. W. Brechbiel, L. J. Burns, A. Panoskaltsis-Mortari, K. E. Dusenbery, D. R. Clohisy, and E. S. Vitetta Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a 90Y-Labeled Anti-CD22 Monoclonal Antibody Clin. Cancer Res., November 1, 2005; 11(21): 7920 - 7928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Brouwers, J. E.M. van Eerd, C. Frielink, E. Oosterwijk, W. J.G. Oyen, F. H.M. Corstens, and O. C. Boerman Optimization of Radioimmunotherapy of Renal Cell Carcinoma: Labeling of Monoclonal Antibody cG250 with 131I, 90Y, 177Lu, or 186Re J. Nucl. Med., February 1, 2004; 45(2): 327 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Froidevaux, M. Calame-Christe, J. Schuhmacher, H. Tanner, R. Saffrich, M. Henze, and A. N. Eberle A Gallium-Labeled DOTA-{alpha}-Melanocyte- Stimulating Hormone Analog for PET Imaging of Melanoma Metastases J. Nucl. Med., January 1, 2004; 45(1): 116 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. FROIDEVAUX, M. CALAME-CHRISTE, L. SUMANOVSKI, H. TANNER, and A. N. EBERLE DOTA {alpha}-Melanocyte-Stimulating Hormone Analogues for Imaging Metastatic Melanoma Lesions Ann. N.Y. Acad. Sci., June 1, 2003; 994(1): 378 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Griffiths, S. V. Govindan, R. M. Sharkey, D. R. Fisher, and D. M. Goldenberg 90Y-DOTA-hLL2: An Agent for Radioimmunotherapy of Non-Hodgkin's Lymphoma J. Nucl. Med., January 1, 2003; 44(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Froidevaux, M. Calame-Christe, H. Tanner, L. Sumanovski, and A. N. Eberle A Novel DOTA-{alpha}-Melanocyte-Stimulating Hormone Analog for Metastatic Melanoma Diagnosis J. Nucl. Med., December 1, 2002; 43(12): 1699 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Juweid Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice J. Nucl. Med., November 1, 2002; 43(11): 1507 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Perico, M. Chinol, A. Nacca, E. Luison, G. Paganelli, and S. Canevari The Humoral Immune Response to Macrocyclic Chelating Agent DOTA Depends on the Carrier Molecule J. Nucl. Med., November 1, 2001; 42(11): 1697 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Froidevaux, A. Heppeler, A. N. Eberle, A.-M. Meier, M. Hausler, C. Beglinger, M. Behe, P. Powell, and H. R. Macke Preclinical Comparison in AR4-2J Tumor-Bearing Mice of Four Radiolabeled 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Somatostatin Analogs for Tumor Diagnosis and Internal Radiotherapy Endocrinology, September 1, 2000; 141(9): 3304 - 3312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Junghans, J. A. Carrasquillo, and T. A. Waldmann Impact of antigenemia on the bioactivity of infused anti-Tac antibody: Implications for dose selection in antibody immunotherapies PNAS, February 17, 1998; 95(4): 1752 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Blake, P. Chakrabarti, M. Khosraviani, F. M. Hatcher, C. M. Westhoff, P. Goebel, D. E. Wylie, and R. C. Blake II Metal Binding Properties of a Monoclonal Antibody Directed toward Metal-Chelate Complexes J. Biol. Chem., November 1, 1996; 271(44): 27677 - 27685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Waldmann Monoclonal antibodies in diagnosis and therapy Science, June 21, 1991; 252(5013): 1657 - 1662. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
